For patients with carotid stenosis ≥50% with a low/intermediate predicted stroke risk, there is no benefit for revascularization added to OMT.

Observational studies at the SCAI meeting favored the dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) over ...